Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Heart Failure with Reduced Ejection FractionEnd Stage Renal Disease on Dialysis
Interventions
DRUG

Empagliflozin 25 MG

The medication will be packed in a customized sealed jar and labeled on the exterior of the jar.

DRUG

Placebo

The placebo tablet is manufactured by Prince Pharmaceutical Co., Ltd, a leading manufacturer of nutritional supplements with certifications including cGMP, GMP, ISO, and HACCP. The Prince Pharmaceutical also provides Original Equipment Manufacturing (OEM)/Original Design Manufacturing (ODM) services for a wide array of tablet shapes, and post-processing techniques such as film coating and sugar coating.

Trial Locations (2)

111

RECRUITING

Shin Kong Wu Ho-Su Memorial Hospital, Taipei

300

RECRUITING

National Taiwan University Hospital Hsinchu Branch, Hsinchu

All Listed Sponsors
collaborator

Shin Kong Wu Ho-Su Memorial Hospital

OTHER

lead

National Taiwan University Hospital

OTHER